vTv Therapeutics (VTVT) Competitors $20.18 +0.23 (+1.15%) As of 12:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTVT vs. CMPX, AVIR, TERN, ACB, SLDB, ATXS, SLRN, CDTX, HUMA, and DRUGShould you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include Compass Therapeutics (CMPX), Atea Pharmaceuticals (AVIR), Terns Pharmaceuticals (TERN), Aurora Cannabis (ACB), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Acelyrin (SLRN), Cidara Therapeutics (CDTX), Humacyte (HUMA), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. vTv Therapeutics vs. Compass Therapeutics Atea Pharmaceuticals Terns Pharmaceuticals Aurora Cannabis Solid Biosciences Astria Therapeutics Acelyrin Cidara Therapeutics Humacyte Bright Minds Biosciences Compass Therapeutics (NASDAQ:CMPX) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability. Does the media favor CMPX or VTVT? In the previous week, Compass Therapeutics had 7 more articles in the media than vTv Therapeutics. MarketBeat recorded 9 mentions for Compass Therapeutics and 2 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.71 beat Compass Therapeutics' score of 0.52 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Compass Therapeutics Positive vTv Therapeutics Positive Which has stronger valuation & earnings, CMPX or VTVT? vTv Therapeutics has higher revenue and earnings than Compass Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompass Therapeutics$850K292.02-$42.49M-$0.37-4.85vTv Therapeutics$1.02M63.30-$20.25M-$3.41-5.92 Is CMPX or VTVT more profitable? Compass Therapeutics' return on equity of -32.37% beat vTv Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Compass TherapeuticsN/A -32.37% -30.67% vTv Therapeutics N/A -184.64%-47.29% Do analysts prefer CMPX or VTVT? Compass Therapeutics presently has a consensus target price of $13.38, suggesting a potential upside of 645.13%. vTv Therapeutics has a consensus target price of $35.50, suggesting a potential upside of 75.92%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than vTv Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11vTv Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, CMPX or VTVT? Compass Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Does the MarketBeat Community prefer CMPX or VTVT? vTv Therapeutics received 306 more outperform votes than Compass Therapeutics when rated by MarketBeat users. However, 81.03% of users gave Compass Therapeutics an outperform vote while only 57.12% of users gave vTv Therapeutics an outperform vote. CompanyUnderperformOutperformCompass TherapeuticsOutperform Votes4781.03% Underperform Votes1118.97%vTv TherapeuticsOutperform Votes35357.12% Underperform Votes26542.88% Do insiders & institutionals have more ownership in CMPX or VTVT? 68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 28.5% of Compass Therapeutics shares are held by company insiders. Comparatively, 1.3% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryCompass Therapeutics beats vTv Therapeutics on 13 of the 18 factors compared between the two stocks. Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTVT vs. The Competition Export to ExcelMetricvTv TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.37M$6.72B$5.49B$7.97BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-4.457.3622.6118.58Price / Sales63.30241.71397.51103.15Price / CashN/A65.8538.1834.62Price / Book-2.186.486.704.26Net Income-$20.25M$143.43M$3.22B$248.31M7 Day Performance-10.31%1.69%1.26%1.34%1 Month Performance23.05%6.58%3.73%3.92%1 Year Performance-27.83%-2.63%15.82%5.33% vTv Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTVTvTv Therapeutics1.7873 of 5 stars$20.18+1.2%$35.50+75.9%-28.5%$64.37M$1.02M-4.459Upcoming EarningsShort Interest ↑News CoverageGap DownCMPXCompass Therapeutics3.3905 of 5 stars$1.78+1.7%$13.38+651.4%+29.2%$246.14M$850,000.00-4.8120Analyst ForecastShort Interest ↑Analyst RevisionAVIRAtea Pharmaceuticals3.1648 of 5 stars$2.86-3.7%$6.00+109.8%-20.3%$244.60MN/A-1.3870Positive NewsTERNTerns Pharmaceuticals4.2798 of 5 stars$2.71+12.9%$18.38+578.0%-34.7%$236.58MN/A-2.3040Positive NewsACBAurora Cannabis0.6363 of 5 stars$4.20-5.4%N/A-49.7%$236.10M$320.81M84.021,340News CoverageSLDBSolid Biosciences3.9803 of 5 stars$3.03+18.8%$15.67+417.1%-62.7%$234.80M$8.09M-1.00100High Trading VolumeATXSAstria Therapeutics2.5439 of 5 stars$4.11+1.7%$26.60+547.2%-43.8%$231.94MN/A-1.9730Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageSLRNAcelyrin2.9976 of 5 stars$2.28+3.6%$9.60+321.1%-40.9%$230.07MN/A-0.93135Positive NewsCDTXCidara Therapeutics4.2432 of 5 stars$20.68+6.4%$39.14+89.3%+74.4%$226.51M$1.28M-0.8190Analyst ForecastNews CoveragePositive NewsHUMAHumacyte2.807 of 5 stars$1.45-13.7%$13.71+845.8%-63.0%$224.92M$1.57M-1.08150News CoverageDRUGBright Minds Biosciences3.326 of 5 stars$31.89-3.7%$84.33+164.5%+2,970.0%$224.63MN/A-187.58N/ANews CoveragePositive NewsGap Down Related Companies and Tools Related Companies CMPX Alternatives AVIR Alternatives TERN Alternatives ACB Alternatives SLDB Alternatives ATXS Alternatives SLRN Alternatives CDTX Alternatives HUMA Alternatives DRUG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTVT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share vTv Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VTVT Stock Free VTVT Stock Alerts